ModuLight.bio

Company Overview

Snapshot

Founded in April 2022 by Ofir Levi, Yotam Eldar, and Daniel Sadot, ModuLight.bio operates with 11–50 employees. The company has raised $6.7 million across two funding rounds from six investors. In July 2025, ModuLight.bio secured funding with Nexus NeuroTech Ventures participating as a lead investor.

Business overview

ModuLight.bio is a Health Tech & Life Sciences company developing an optogenetics-based platform designed to treat neuronal overactivation disorders. The company's core technology focuses on neuro-stimulation and pharmaceuticals, aiming to revolutionize the treatment of severe neurological conditions. ModuLight.bio operates within the Pharma & Medical Biotechnology sector, specifically in Drugs Discovery & Development, and serves the Pharmaceuticals market in Europe and North America.

Company Intelligence Q&A

What is ModuLight.bio's primary focus?

ModuLight.bio is developing an optogenetics-based platform for treating neuronal overactivation disorders, aiming to revolutionize the treatment of severe neurological conditions.

When was ModuLight.bio founded and by whom?

ModuLight.bio was founded in April 2022 by Ofir Levi, Yotam Eldar, and Daniel Sadot.

Which investors participated in ModuLight.bio's July 2025 funding round?

In July 2025, ModuLight.bio secured funding with Nexus NeuroTech Ventures as a lead investor.

What is ModuLight.bio's current employee count?

ModuLight.bio currently has 11–50 employees.

What is the total capital raised by ModuLight.bio?

ModuLight.bio has raised a total of $6.7 million across two funding rounds.